The QualityStocks Daily Thursday, October 24th, 2024

Today's Top 3 Investment Newsletters

QualityStocks(MNPR) $4.6300 +605.40%

MarketClub Analysis(NXU) $0.2503 +139.15%

Schaeffer's(TSLL) $9.0100 +43.73%

The QualityStocks Daily Stock List

Monopar Therapeutics (MNPR)

StreetInsider, MarketClub Analysis, QualityStocks, MarketBeat, The Stock Dork, Timothy Sykes, The Online Investor, stockstotrade, StockMarketWatch and 360 Wall Street reported earlier on Monopar Therapeutics (MNPR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Monopar Therapeutics Inc. (NASDAQ: MNPR) (FRA: 1IY) is a clinical-stage biopharmaceutical firm that is focused on the development of proprietary therapeutics to improve clinical outcomes for cancer patients.

The firm has its headquarters in Wilmette, Illinois and was incorporated in December 2014, by Andrew P. Mazar, Christopher M. Starr and Chandler D. Robinson. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers in the United States.

The company is party to a collaboration agreement with the Cancer Science Institute of Singapore, which entails evaluating MNPR-202 activity and related analogs in various types of cancer. It is also party to a collaboration with NorthStar Medical Radioisotopes LLC, for the development of radio-immuno-therapeutics which target severe coronavirus infections; and another with Grupo Español de Investigaciónen Sarcomas, to develop camsirubicin for patients with advanced soft tissue sarcoma.

The enterprise’s product portfolio is made up of a topoisomerase II-alpha targeted doxorubicin analog known as Camsirubicin, which has been designed to retain anti-cancer activity and minimize the toxic effects of therapies on patients’ hearts; and a clonidine mucobuccal tablet dubbed Validive, which is undergoing a phase 2 trial testing its efficacy in treating radiation induced severe oral mucositis in patients with oropharyngeal cancer. It also develops a humanized monoclonal antibody dubbed MNPR-101, to treat advanced cancers and preclinical stage severe coronavirus infections.

The success of the company’s camsirubicin drug, which has shown potential signs of anti-tumor activity, will benefit patients with cancer while bringing in more investors into the company, which will boost its growth significantly.

Monopar Therapeutics (MNPR), closed Thursday's trading session at $32.66, up 605.3996%, on 19,963,354 volume. The average volume for the last 3 months is 3.601M and the stock's 52-week low/high is $1.3695/$38.50.

Clean Vision (CLNV)

QualityStocks and MarketClub Analysis reported earlier on Clean Vision (CLNV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Clean Vision Corporation (OTCQB: CLNV) is an investment firm that is focused on investing in technologies and firms in the clean energy sector.

The firm has its headquarters in Manhattan Beach, California and was incorporated in 2003, on February 24th. The firm serves consumers around the globe.

The company is focused on acquiring sustainable clean technologies and green energy firms which will have an impact in the green economy and help serve the global market’s needs of today as well as the future. Its objective is to become a leader in the technology mergers and acquisitions space and cement its position as a trusted technical partner and technology consultant to large firms. The company’s subsidiaries include Clean-Seas Inc., a solutions provider which develops plastic recycling technologies to help decrease the amount of plastic waste which flows into oceans around the world.

The enterprise helps businesses improve their clean energy technology and supports ventures in the green economy which will help decrease greenhouse gas emissions, improve quality of life for consumers, provide economic growth and significant job opportunities, as well as add value to its shareholders. In addition to this, the enterprise provides packaging services.

The company is planning to customize its AquaH clean hydrogen fuel cell for installation with the pyrolysis plant, which is being developed in partnership with the Indian Institute of Chemical Technology. This good environmental solution will add great value to the company’s shareholders, which will encourage more investments into the company and boost its growth.

Clean Vision (CLNV), closed Thursday's trading session at $0.0314, up 25.6%, on 7,697,381 volume. The average volume for the last 3 months is 617,898 and the stock's 52-week low/high is $0.00885/$0.0565.

DBV Technologies S.A. (DBVT)

StockMarketWatch, MarketBeat, BUYINS.NET, Marketbeat.com, Schaeffer's, Daily Trade Alert, QualityStocks, The Street, Trades Of The Day, VectorVest, MarketClub Analysis, The Wall Street Transcript, TraderPower, TradersPro, StockEarnings, StreetInsider, The Stock Dork, Barchart, InvestorPlace and INO.com Market Report reported earlier on DBV Technologies S.A. (DBVT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DBV Technologies S.A. (NASDAW: DBVT) (FRA: DBV) is a clinical-stage biopharmaceutical firm that is focused on the research and development of epi-cutaneous immunotherapy products.

The firm has its headquarters in Montrouge, France and was incorporated in 2002, on March 29th by Pierre-Yves Vannerom, Christophe Dupont, Bertrand Dupont, Stéphane Benhamou and Pierre-Henri Benhamou. It serves consumers across the globe.

The company is party to a collaboration agreement with Nestle Health Science, which entails the development of a ready-to-use atopy patch test known as MAG1C, which has been designed to diagnose non-IgE mediated CMPA in toddlers and infants. The company is also involved in exploring potential applications of its platform in vaccines and other immune ailments.

The enterprise’s product pipeline comprises of an electrostatic patch dubbed Viaskin which provides a self-administered, non-invasive and convenient immunotherapy to patients. It also produces an immunotherapy product known as Viaskin Peanut which has concluded phase 3 clinical trials testing its effectiveness in treating peanut allergies in children aged between 4 and 11. Additionally, the enterprise is involved in the development of a pre-clinical stage product known as Viaskin Egg for treating hen’s egg allergy and Viaskin Milk, which is undergoing a phase I/II clinical trial and has been designed to treat milk-induced eosinophilic esophagitis and Immunoglobulin E mediate protein allergy for cow’s milk. It also produces a booster vaccine for Bordetella pertussis.

Forecasts show that the global allergy immunotherapy market will grow significantly in the next couple of years, increasing its value considerably by 2030. The firm’s involvement in the market positions it for growth as well as expansion given the significantly unmet needs of patients living with various illnesses that require the firm’s expertise.

DBV Technologies S.A. (DBVT), closed Thursday's trading session at $0.8375, up 23.1437%, on 7,077,801 volume. The average volume for the last 3 months is 2.975M and the stock's 52-week low/high is $0.5024/$2.28.

Elite Pharmaceuticals (ELTP)

QualityStocks, Stockpalooza, PennyTrader Publisher, PennyStocks24, OTCPicks, MarketBeat, Real Pennies, Marketbeat.com, MarketMovingTrends, PennyStock MarketBulls, MadPennyStocks, SmarTrend Newsletters, Capital Equity Report, PennyInvest, Greenbackers, First Penny Picks, RagingStock Bull, OTCBB Journal, TopPennyStockMovers, StockEgg, Pennybuster, Top Stock Picks, Stock Analyzer, BullRally, StockRich, MarketClub Analysis, StocksImpossible, The Daily Market Alert, Beacon Equity Research, TheMicrocapNews, GoldminePennyStocks, HotOTC, CoolPennyStocks, Buzz Stocks, Money Wealth Matters, FeedBlitz, DividendStocks, CRWEPicks, Wise Alerts, HotStockChat, Stock Preacher, SmallCap Network, SmallCapVoice, Pumps and Dumps, Promotion Stock Secrets, Planet Penny Stocks, PennyStockVille, Stock Fortune Teller, Member Signals, WiseAlerts, MicrocapVoice, Alternative Energy, Penny Stock Rumble, Penny Pick Finders, Penny Invest, StockOnion, OTC Advisors, SecretStockPromo and PennyStockProphet reported earlier on Elite Pharmaceuticals (ELTP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Elite Pharmaceuticals Inc. (OTCQB: ELTP) is a pharmaceutical firm that is focused on conducting research on, developing, manufacturing and licensing drug delivery products and systems.

The firm’s headquarters are in the state of New Jersey, United States and was incorporated in 1997, on October 1st. It operates as part of the healthcare industry, under the biotech and pharma sub-industry. The firm serves consumers around the globe.

The company is party to a strategic marketing alliance with Lannett Company Inc. and Glenmark Pharmaceuticals Inc. It is also party to a development and license agreement with SunGen Pharma LLC.; and a manufacturing and license agreement with Epic Pharma LLC. The company operates through the New Drug applications for branded and generic products.

The enterprise’s products include Isradipine capsules for cardiovascular ailments; Naltrexone tablets for pain management; Phendimetrazine Tartrate tablets for bariatrics; and HydromorphoneHCl tablets for pain. It also offers Methadone HCl tablets for pain; Trimipramine Maleate Immediate Release antidepressant capsules; Amphetamine sulfate immediate release, Dextroamphetamine sulfate and Dextroamphetamine saccharate tablets for central nervous system diseases. In addition to this, the enterprise manufactures controlled-release products on a contract basis for 3rd parties, in the areas of infection, bariatric, allergy and pain. The enterprise is also focused on the development of a range of abuse deterrent opioid products.

The firm recently released it latest financial results for the year 2021, which show increases in its revenues and profits. Currently, it is focused on diversifying its products in order to stabilize the firm and support its growth.

Elite Pharmaceuticals (ELTP), closed Thursday's trading session at $0.57549, up 22.3926%, on 4,252,872 volume. The average volume for the last 3 months is 96,720 and the stock's 52-week low/high is $0.10/$0.7549.

Talphera Inc. (TLPH)

Epic Stock Picks, Wolf of Penny Stocks, Secret Stock Club, Stocks Gone Wild, EpicVIP Group, Stock Stars, Real Pennies, MonsterStocksPicks and MarketBeat reported earlier on Talphera Inc. (TLPH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Talphera Inc. (NASDAQ: TLPH) (FRA: R5XA) is a specialty pharmaceutical firm focused on developing and commercializing treatments for use in medically supervised settings.

The firm has its headquarters in San Mateo, California and was incorporated in 2005, on July 13th by Pamela Pierce Palmer and Thomas A. Schreck. Prior to its name change in January 2024, the firm was known as AcelRx Pharmaceuticals Inc. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm has its headquarters in San Mateo, California.

Talphera’s product candidates include Niyad, a lyophilized formulation of nafamostat, focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. It is also developing LTX-608,an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. In addition to this, the enterprise develops PFS-02, a pre-filled phenylephrine syringe; and Fedsyra, a pre-filled ephedrine syringe.

The company recently announced its latest financial and operational results, with its CEO revealing that they’d already acquired Breakthrough Device Designation from the FDA for Nafamostate. This provides an advantage for a timely approval of the product candidate next year, bringing the company closer to addressing the known disadvantages of currently available U.S. products for anticoagulation of the extracorporeal circuit. It could also encourage additional investments into Talphera Inc.

Talphera Inc. (TLPH), closed Thursday's trading session at $0.959, off by 1.134%, on 90,443 volume. The average volume for the last 3 months is 12.624M and the stock's 52-week low/high is $0.425/$1.61.

Meta Platforms Inc. (META)

Zacks, The Street, InvestorPlace, Early Bird, Schaeffer's, Investopedia, MarketClub Analysis, MarketBeat, The Online Investor, Kiplinger Today, INO Market Report, Cabot Wealth, TipRanks, Top Pros' Top Picks, QualityStocks, Louis Navellier, The Daily Market Alert, Money Wealth Matters, The Night Owl, DividendStocks, AllPennyStocks, Trading Tips, MarketMovingTrends, TradersPro, InsiderTrades, Daily Wealth, Investment House, Eagle Financial Publications, FreeRealTime, TradeSmith Daily, Trading with Larry Benedict, InvestorIntel, TradingPub, Inside Trading, The Wealth Report, Rick Saddler, Market Trends, CNBC Breaking News, Smartmoneytrading, Jon Markman’s Pivotal Point, Investing Daily, Investing Breakout, Investors Underground, Earnings360, Jea Yu, Contrarian Outlook, bullseyeoptiontrading, Trade Out Loud, StockReport, Marketbeat.com, Top Pros Top Picks, The Stock Dork, Smart Investing Society, Stansberry Research, Timothy Sykes, wyatt research newsletter, Trading Pub, Don Kaufman, Investor's Business Daily, Chaikin Analytics, Financial Newsletter, Tim Bohen, The SmartMoneyTrading, 360 Wall Street, The Investing Insider, empirefinancialresearch, TheoTrade, Prism MarketView, Hit and Run Candle Sticks, iDigital Market, Premium Stock Alerts, OTC Stock Review, On Options, Mind Over Markets, 1 2 3 Trade Option, TradeSmith, Wealth Daily, Investor News, Jeff Bishop and Empire Financial Daily reported earlier on Meta Platforms Inc. (META), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last week, Meta Platforms Inc. (NASDAQ: META) announced that it’d be launching new artificial intelligence models from its research division. The new models, which would include an evaluator that’s self-taught, may reduce the involvement of humans in the AI development process.

They also support Meta’s objective of achieving advanced machine intelligence while also supporting reproducibility and open science.

The launch follows the company’s introduction of the tool in a paper which explained how it depended on the same technique used by the recently rolled out o1 models to make reliable judgments about responses given by a model. This technique breaks down issues into smaller steps and may enhance the accuracy of responses on difficult problems in subjects like math, coding, and science.

Researchers at Meta under Fundamental AI Research (FAIR) used data generated from artificial intelligence to train the evaluator model, which did away with human input at that stage. The FAIR team is committed to using advanced machine intelligence to power innovation and products for the benefit of every individual.

Two researchers behind the project explained in an interview that the use of AI in assessing itself provided a glimpse into a potential pathway toward designing autonomous artificial agents that can learn from their own errors.

It is expected that self-improving models will eliminate the need for reinforcement learning from human feedback, which is a costly and inefficient process that needs input from humans who must have the expertise required to accurately label data and verify that answers to writing and math queries are correct.

One Meta researcher, Jason Weston, hopes that as artificial intelligence becomes more super-human it will get better at verifying its work so that it’s better than the average human. Weston adds that the idea of being able to self-evaluate and be self-taught is pivotal to getting artificial intelligence to the super-human level.

Other artificial intelligence tools released by Meta include a tool that speeds up the generation times of large language models’ responses, an update to its Segment Anything image-identification model, and datasets that can assist in discovering new inorganic materials.

Other firms that have published research on Reinforcement Learning from Artificial Intelligence Feedback include Anthropic and Google. Unlike Meta though, these firms haven’t released their models for use by the public.

FAIR researchers hope that their work will inspire iteration and help advance artificial intelligence in a responsible way, helping bring the world closer together. They believe that access to state-of-the-art AI creates opportunities for all.

Meta Platforms Inc. (META), closed Thursday's trading session at $567.78, up 0.7255761%, on 7,184,651 volume. The average volume for the last 3 months is 157,364 and the stock's 52-week low/high is $279.403/$602.95.

Calidi Biotherapeutics Inc. (CLDI)

QualityStocks, MarketBeat and Premium Stock Alerts reported earlier on Calidi Biotherapeutics Inc. (CLDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, is set to present data on its innovative systemic antitumor virotherapy platform, RTNova (CLD-400), at multiple scientific conferences. These include the International Oncolytic Virotherapy Conference in Rotterdam (Oct. 27-30), the Immuno US 2024 in San Diego (Oct. 28-29), and the Society for Immunotherapy of Cancer Annual Meeting in Houston (November 6-10).

RTNova is designed to address the challenges posed by untargetable and untreatable metastatic diseases by targeting multiple tumor sites and altering the tumor immune microenvironment. This approach not only facilitates easier administration but also broadens the potential patient population who can benefit from this treatment.

“RTNova represents a groundbreaking advancement in cancer therapy, offering a systemic approach that enables us to target and treat metastatic tumors that were previously untouchable,” said Dr. Antonio F. Santidrian, Calidi’s Chief Scientific Officer who has been instrumental in advancing the development of the RTNova platform. “RTNova’s ability to fundamentally change the tumor microenvironment while delivering therapeutic viruses to multiple tumor sites has the potential to unlock new possibilities for patients facing some of the most challenging cancers. Ultimately, we believe RTNova has the potential to transform how we address previously untreatable metastatic diseases.”

To view the full press release, visit: https://ibn.fm/n8hZT

About Calidi Biotherapeutics

Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.

For more information, please visit www.calidibio.com

Calidi Biotherapeutics Inc. (CLDI), closed Thursday's trading session at $0.84, up 1.1926%, on 260,294 volume. The average volume for the last 3 months is 15.685M and the stock's 52-week low/high is $0.8016/$29.30.

CBD Life Sciences (CBDL)

QualityStocks, StockRockandRoll, PennyStockLocks, Penny Stock 101 and FreeRealTime reported earlier on CBD Life Sciences (CBDL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CBD Life Sciences (OTC: CBDL) today announced its potential for explosive profits in a $70 billion industry and, with its innovative product line and strategic market positioning, standing ready to deliver unparalleled returns for shareholders. “The U.S. is on the verge of a historic shift. With the Biden administration, led by Vice President Kamala Harris, taking bold steps toward federal marijuana legalization, the opportunities for companies in the cannabis and CBD sectors are poised to skyrocket,” the announcement reads. “According to industry projections, the legal cannabis market in the U.S. is expected to surpass $70 billion by 2028, driven by a surge in demand for both recreational and medicinal products. This creates a vast new revenue stream not only for marijuana companies but also for CBD businesses, which are uniquely positioned to tap into the wellness and therapeutic segments. CBDL, with its innovative product range and robust retail partnerships, is perfectly aligned to seize this opportunity.”

To view the full press release, visit https://ibn.fm/LnsqE

About CBD Life Sciences Inc.

CBD Life Sciences is a leading innovator in the CBD and wellness industry, committed to creating high-quality, scientifically backed products that promote health and well-being. From pain relief to overall wellness, CBD Life Sciences strives to deliver top-tier solutions that meet the needs of today's consumers. For more information about CBD Life Sciences and its product offerings, visit www.thecbdvault.com.

CBD Life Sciences (CBDL), closed Thursday's trading session at $0.0006, even for the day, on 21,516,983 volume. The average volume for the last 3 months is 17.413M and the stock's 52-week low/high is $0.0003/$0.03.

Trump Media & Technology Group Corp. (DJT)

Schaeffer's, QualityStocks, Premium Stock Alerts, 360 Wall Street, Wealth Daily, Early Bird, AllPennyStocks, Tim Bohen, The Street, MarketClub Analysis, Investors Underground, Energy and Capital, Eagle Financial Publications and Cabot Wealth reported earlier on Trump Media & Technology Group Corp. (DJT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trump Media & Technology Group (NASDAQ: DJT) has launched its Truth+ streaming app for Android TV. This app offers diverse content, including news, entertainment and children’s programming, available through linear TV and Video on Demand (“VOD”). It enhances the Truth Social platform with features like live TV rewind and a Spanish language interface.

CEO Devin Nunes emphasizes the importance of expanding to Android TV, complementing the existing Apple TV platform. This move aims to strengthen Truth Social as a hub for news and entertainment. DJT plans to extend Truth+ to other platforms like Samsung, LG, Amazon Fire, and Roku, enhancing its reach.

DJT’s streaming service operates on a custom Content Delivery Network (“CDN”), using its own servers to maintain independence from major tech companies. This aligns with DJT’s mission to provide a platform for free speech, countering perceived Big Tech censorship.

Currently, DJT’s stock price on Nasdaq is $34.48, down 3.98% or $1.43. The stock has fluctuated between $33.09 and $34.90 today. Over the past year, DJT has seen a high of $79.38 and a low of $11.75, with a market cap of about $6.9 billion and a trading volume of 11.79 million shares.

To view the full press release, visit https://ibn.fm/n4Avg

About Trump Media & Technology Group Corp.

The mission of Trump Media & Technology Group is to end Big Tech’s assault on free speech by opening up the internet and giving people their voices back. Trump Media & Technology Group operates Truth Social, a social media platform established as a safe harbor for free expression amid increasingly harsh censorship by Big Tech corporations. For more information, visit the company’s website at www.TMTGCorp.com.

Trump Media & Technology Group Corp. (DJT), closed Thursday's trading session at $34.95, off by 2.6734%, on 42,145,634 volume. The average volume for the last 3 months is 1.123M and the stock's 52-week low/high is $11.75/$79.38.

Aurora Cannabis Inc. (ACB)

InvestorPlace, Schaeffer's, StocksEarning, MarketClub Analysis, MarketBeat, QualityStocks, The Street, StockEarnings, Trades Of The Day, Daily Trade Alert, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, Kiplinger Today, StockMarketWatch, CFN Media Group, Investopedia, CannabisNewsWire, Stock Up Featured, Early Bird, Profit Trends, BUYINS.NET, The Rich Investor, BlackSwanAlert, StreetAuthority Daily, Jim Cramer, TheoTrade, Cannabis Financial Network News, CNBC Breaking News, Inside Trading, Daily Profit, Investors Alley, Investors Underground, Market Intelligence Center, Outsider Club, Zacks, Technology Profits Daily, The Wealth Report, TheTradingReport, Top Pros' Top Picks, Tradespoon, Wall Street Window and Money and Markets reported earlier on Aurora Cannabis Inc. (ACB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Two new studies funded by the federal government may help reduce some concerns about cannabis use during pregnancy. One study found no link between early cannabis use in pregnancy and the development of autism in children, while the other showed no connection to an increased risk of developmental delays in early childhood.

Both studies analyzed pregnancy outcomes where the mother either self-reported marijuana use or tested positive for THC during prenatal visits, typically around the second month of pregnancy.

The autism-related study included information from 146,296 individuals involved in 178,948 pregnancies from 2011 to 2019. The study on developmental delays included information from 106,240 adults and 119,976 pregnancies from early 2015 to late 2019. The kids underwent tests at different phases to check for developmental milestones and autism.

The autism study concluded that prenatal marijuana use was not linked to childhood autism after accounting for factors such as socioeconomic status, other substance use, and maternal health conditions. Likewise, the developmental delay study found no evidence that cannabis use in early pregnancy was associated with delays in motor skills, speech or language, or overall developmental impairment.

However, both studies caution that the results should not be interpreted as indicating that marijuana use during pregnancy is entirely safe, especially with heavy or frequent use. The autism study’s authors did note that, despite the lack of a general link to autism, there might be one with frequent cannabis use, underscoring the need for additional investigation in this field.

One notable finding in the developmental study was a slight reduction in speech and language delays when only urine test results were considered for cannabis use. This finding did not appear in the self-reported data on marijuana use.

The studies also align with recommendations from both the American Academy of Pediatrics and the American College of Obstetrics and Gynecology, which advise pregnant people to avoid marijuana use. The authors recommend that people who are pregnant or planning to become pregnant should be informed of the potential risks marijuana poses to fetal and newborn health.

The research teams stated that their work represents one of the largest investigations into maternal cannabis use during pregnancy. While their results are consistent with most studies on childhood development following prenatal cannabis use, the researchers acknowledged that some earlier research had suggested a negative impact. They also pointed out that their findings differ from a 2023 study that reported a connection between cannabis use and autism in children.

These studies align with what many in the cannabis industry, such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), have always wanted government-funded studies to reaffirm so that the claims by prohibitionists are proved wrong.

Aurora Cannabis Inc. (ACB), closed Thursday's trading session at $5.67, off by 4.0609%, on 1,135,129 volume. The average volume for the last 3 months is 410,075 and the stock's 52-week low/high is $2.84/$9.35.

Curaleaf Holdings Inc. (CURLF)

InvestorPlace, QualityStocks, Kiplinger Today, MarketBeat, Cabot Wealth, Daily Trade Alert, Top Pros' Top Picks, The Online Investor, CannabisNewsWire, MarketClub Analysis, Profit Trends, Wealth Insider Alert, StreetInsider, Early Bird, Trading For Keeps, Trades Of The Day, The Street, TradersPro, Prism MarketView, StreetAuthority Daily, Schaeffer's, Zacks, Wyatt Investment Research, Daily Profit, CFN Media Group, wyatt research newsletter and Investment U reported earlier on Curaleaf Holdings Inc. (CURLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A new poll has discovered that roughly 21% of individuals over the age of 50 have used a form of marijuana with THC at least once in the last 12 months. Another 12% admitted to using marijuana on a monthly basis.

The poll, conducted by the University of Michigan, also found that 81% of older adults used marijuana to feel good or relax while 68% did so to improve their sleep. 63% also admitted to using the drug to alleviate pain while 53% did so to manage mental health conditions.

The medical director of Caron’s Older Adult Program, Dr. Barbara Krantz, revealed that her practice had observed a considerable increase in the use of marijuana by individuals aged 50 and above. She explained that most of the older adults grew up in the 60s or 70s, which meant that most may have had earlier life experiences with cannabis and were more open to using the drug.

She added that while they were probably familiar with the effects of the drug, a false sense of comfort was dangerous. This is especially since the cannabis sold to consumers now is stronger, which may make it harder for an individual’s body to process.

Krantz highlighted several potential dangers linked to marijuana use for older individuals, including:

  • Delayed reaction times that may impair driving, leading to accidents
  • Issues with balance that may cause breaks and falls
  • Increased risk of cardiovascular events
  • Interaction with other drugs, which may reduce effectiveness or heighten toxicity
  • Accidental poisoning
  • Psychosis
  • Increased depression, anxiety, or anger
  • Increased cognitive impairment
  • Worsening of chronic obstructive pulmonary disease

A licensed social worker, Shari B. Kaplan, stated that marijuana’s interactions with other medications can be particularly fatal. Kaplan, who’s also a plant medicine formulator, explained that drugs for blood pressure or blood thinners needed to be managed carefully for those who’d like to use marijuana.

She noted that patients may benefit from working with a medical marijuana physician, adding that it was important to discuss marijuana use with one’s health care provider before using any products.

The report also touched on things older individuals needed to be aware of prior to consuming marijuana. Botanical Sciences founder, Dr. Robin Fowler, recommended that seniors start using marijuana at low doses, especially if they were new to the drug.

Fowler added that it was also important that individuals source their marijuana products from licensed dispensaries to ensure product safety and quality.

In jurisdictions where companies like Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) are licensed to operate, seniors can conveniently access medical marijuana products. Studies need to be done focusing on states that prohibit marijuana so that data can be collected on how those in need of these products get them, and how much reliable information they access on the suitable ways of managing their symptoms.

Curaleaf Holdings Inc. (CURLF), closed Thursday's trading session at $3.34, off by 2.0528%, on 324,945 volume. The average volume for the last 3 months is 1.953M and the stock's 52-week low/high is $2.51/$6.40.

Workhorse Group Inc. (WKHS)

Green Car Stocks, InvestorPlace, QualityStocks, MarketClub Analysis, Schaeffer's, Kiplinger Today, StocksEarning, StockEarnings, MarketBeat, StockMarketWatch, TradersPro, StreetInsider, Early Bird, The Street, GreenCarStocks, Trades Of The Day, The Online Investor, TopPennyStockMovers, Daily Trade Alert, TraderPower, BUYINS.NET, Zacks, Money Wealth Matters, Wealth Insider Alert, InvestorsUnderground, Jason Bond, Cabot Wealth, Marketbeat.com, PoliticsAndMyPortfolio, StockOodles, The Night Owl, Profitable Trader Authority, Wealth Daily, Stock Beast, Energy and Capital, The Best Newsletters, Daily Market Beat, The Wealth Report and Premium Stock Alerts reported earlier on Workhorse Group Inc. (WKHS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Drivers may have access to fast-charging battery electric vehicles that can charge from ordinary power outlets in the near future, thanks to innovative transistors. EV charging still represents one of the largest barriers to electric vehicle adoption due to the extended charging periods associated with standard EV chargers. For electric vehicles to enjoy mass adoption, they should be able to recharge as quickly and conveniently as gas-powered cars.

With manufacturers working on various means of enabling fast charging that doesn’t reduce an EV battery’s total lifespan, innovations in transistor technology could provide them with the breakthrough they need to finally develop quick-charging electric cars. Such electric cars would be able to charge from household outlets, eliminating the need to install private electric vehicle chargers and lowering the cost and space requirements of EV ownership.

Fraunhofer Institute for Reliability and Microintegration IZM and the Technical University of Berlin researchers on the EnerConnect project are currently studying bidirectional blocking gallium nitride (GaN) transistors to inform the design of systems that can function with the next generation of active rectifiers and active converters. This type of transistor hardware doesn’t require a separate stage for conversion and has a 99% efficiency rate, thus the potential for significantly more efficient home electric vehicle charging.

While electric vehicle drivers can already charge their vehicles at home using their regular wall outlets, the conversion from alternating current to direct current is highly inefficient, leading to significant energy losses. Even private dedicated electric vehicle chargers installed in the garage or driveway still suffer from this inefficiency issue. As such, researchers from the EnerConnect project have joined hands with industry partners Infineon Technologies AG, Delta Electronics Inc., and BIT GmbH, to develop a system that uses bidirectional blocking gallium nitride transistors.

As bidirectional blocking GaN transistors allow for increased energy density and charging efficiency, they could open the door to electric vehicles that can quickly charge from a regular household outlet. Manufacturers currently use unidirectional blocking transistors that allow cheaper hardware to handle higher switching frequencies but can only lock voltage in a single direction.

Bidirectional blocking transistors, on the other hand, feature two gate structures that allow them to handle both positive and negative voltages, making their use in public grid converters and rectifiers incredibly feasible and potentially beneficial. Deploying this new switching technology would reduce the strain on public charging infrastructure as drivers will have access to efficient home charging without having to invest in home chargers.

It is exciting to imagine the possibilities that will be opened up for various EV models like those made by Workhorse Group Inc. (NASDAQ: WKHS) once quickly charging the EV becomes as simple as plugging it into any power outlet in one’s home.

Workhorse Group Inc. (WKHS), closed Thursday's trading session at $0.7875, off by 0.6434519%, on 746,749 volume. The average volume for the last 3 months is 67,325 and the stock's 52-week low/high is $0.5725/$9.00.

The QualityStocks Company Corner

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT) .

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care, was recognized with the 2024 Digital Health Hub Rising Star award in the ‘Home Health Diagnostic' category at the HLTH global healthcare conference. The award highlights HeartBeam's innovative vector-based technology, which captures heart electrical signals in three dimensions to provide detailed cardiac insights. CEO Rob Eno emphasized the importance of timely care in cardiac health, praising the team's efforts in developing a cable-free, credit card-sized ECG device, currently under FDA review, as a step towards personalized, AI-driven cardiac care.

To view the full press release, visit https://ibn.fm/1ZLrn

HeartBeam Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector 12-lead electrocardiogram (ECG) platform for heart attack detection anytime, anywhere. The company’s proprietary ECG telehealth technology aims to redefine the way high risk cardiovascular patients are diagnosed in ambulatory and acute care settings. HeartBeam’s initial focus is on providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

In August 2022, HeartBeam announced that it submitted its HeartBeam AIMI™ software for approval from the U.S. Food and Drug Administration (FDA). HeartBeam AIMI is a platform technology to improve the speed and accuracy of heart attack detection in acute care settings. The company expects FDA approval by the end of 2022, and a full commercial roll-out of HeartBeam AIMI is targeted for Q1 2023.

HeartBeam sees submission of its first product based on its platform technology as an important milestone toward commercialization, which underscores the company’s continued progress toward making the HeartBeam AIMI platform widely available to help emergency department physicians quickly and accurately identify a heart attack.

While the FDA conducts its regulatory review, HeartBeam will focus on executing key components of its commercialization plan and subscription revenue model. It will also continue to engage in discussions with strategic institutions, including academic centers, regional healthcare systems and regional community hospital systems that can utilize HeartBeam products.

The company is based in Santa Clara, California.

Products

HeartBeam’s development portfolio includes two products:

  • HeartBeam AIMI is software that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack in acute care settings and, as noted above, has been submitted for FDA approval; and
  • HeartBeam AIMIGo™, the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system for remote heart attack detection.

HeartBeam is developing AIMIGo, a medical-grade detection and monitoring technology for use in remote heart attack detection, thereby allowing physicians to diagnose a patient’s heart attack as it occurs, even if the patient is not at a medical facility. The company’s system, once approved by the FDA, can be used by patients at home or almost anywhere and anytime to help their physicians assess whether chest pain is the result of a heart attack or another cause. While approximately 82% of chest pain ED visits are unnecessary, patients delay approximately 3 to 4 hours after symptoms begin, increasing mortality rates by 40%. The company’s goal is to shorten the time to treatment outside of the medical facility to improve patients’ well-being.

HeartBeam’s AIMIGo is a powerful, portable and easy-to-use prescription-based product. It comprises a smartphone app, a credit card-sized ECG device placed on a patient’s chest, the HeartBeam cloud platform, and a digital portal for the physician to view ECG results and direct patient action. For the first time outside of a medical setting, HeartBeam AIMIGo enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if needed.

Pending FDA clearance, AIMIGo is initially intended to be available by prescription, and is reimbursable under existing remote patient monitoring codes (RPM codes). This provides a new revenue stream to physicians who before did not have a way to monitor these high-risk patients. The RPM codes provide a monthly reoccurring revenue stream to the company, as well. On average, at current reimbursement rates, the practice will receive $1,300+ per year per patient they monitor, and the company will receive $600 per year per patient from this RPM reimbursement.

Market Overview

Adoption rates of telehealth services increased dramatically in recent years, with the COVID-19 pandemic serving as a major driver of growth. Among the areas seeing the greatest expansion are cardiology, radiology, behavioral health and online consultation.

Encouraging this growth, governments are actively developing new policies and reimbursement guidelines to promote the use of digital health platforms. The U.S. Centers for Medicare & Medicaid Services (CMS), for example, has recently expanded reimbursement for telehealth services. U.S. market growth is also being driven by the rising prevalence of chronic conditions and the growing geriatric population.

Remote heart attack detection is a previously unsolved problem with a massive and underserved market that is several times larger than the $2 billion total addressable market (TAM) in the U.S. for ECG cardiac arrhythmia monitoring.

Approximately 8 million Americans have suffered at least one heart attack, and a total of 18 million have been diagnosed with coronary artery disease (CAD). Based on these figures, HeartBeam projects a total addressable U.S. market TAM valued at $10 billion annually for its AIMIGo solution for remote heart attack monitoring of CAD.

Management Team

Branislav Vajdic, Ph.D., Chief Executive Officer and Founder of HeartBeam, Inc, combines over 30 years of experience in technology development and senior management positions. Dr. Vajdic has been deeply involved with the development of HeartBeam’s technology to fit his vision for the company. Prior to HeartBeam, from 2007 to 2010, Dr. Vajdic was CEO and Founder of NewCardio, a publicly traded company in the cardiovascular devices space. From 1984 to 2007, Dr. Vajdic was at Intel, where he held various senior management position. At Intel, Dr. Vajdic was the designer of first Flash memory and two key inventions that enabled Flash as a product and led engineering groups responsible for Pentium 1 through Pentium 4 designs. Dr. Vajdic was awarded two Intel Achievement Awards, the highest level of award for outstanding contributions to Intel. Dr. Vajdic is author of numerous patents and publications in the fields of cardiovascular devices, as well as chip design. Dr. Vajdic holds a Ph.D. in Electrical Engineering from the University of Minnesota.

Jon Hunt, Ph.D., has over 35 years’ experience in the medical/medical device industry with extensive domestic and international experience in general management, clinical/regulatory, sales and marketing. He also has diverse experience in Fortune 500 companies, as well as start-up environments. Dr. Hunt was the Vice President of Clinical Science and Technology, Medical Device Innovation Consortium, from July 2019 to July 2021, and Vice President of Clinical and Regulatory Affairs, Cryterion Medical from January 2018 to June 2019 (acquired by Boston Scientific Corporation in July 2018 for $202M). Dr. Hunt was the Founding President and CEO of Bardy Diagnostics, Inc. from October 2013 to November 2017 (acquired by Hill-Rom Holdings, Inc.). Prior to joining Bardy Diagnostics, Dr. Hunt spent the previous 11 years as the Vice President of Clinical & Regulatory Affairs with Cameron Health, Inc. (acquired by Boston Scientific Corporation). Dr. Hunt spent the previous 10 years with Cardiac Pacemakers, Inc., St. Jude Medical and Cardiac Pathways Corporation. Dr. Hunt began his career with Cardiac Pacemakers, Inc. (now Boston Scientific Corporation) as the Director of Clinical Programs. He subsequently held positions at St. Jude Medical in Clinical Affairs and as the Business Unit Director for the Cardiac Rhythm Management division for Europe, the Middle East and Africa. At Cardiac Pathways Corporation, Dr. Hunt held various executive positions as Vice President of International Sales and Marketing and Vice President of Worldwide Sales and Marketing (acquired by Boston Scientific Corporation). Dr. Hunt received his Ph.D. in Motor Control from The Pennsylvania State University, his Master’s from California State University, Long Beach and his undergraduate degree from Keele University in the United Kingdom.

Rick Brounstein, HeartBeam’s Chief Financial Officer, combines over 30 years of experience in health technology senior management. Since 2017, Mr. Brounstein has been and is currently a partner of Hardesty, LLC, a financial services firm, and Mr. Brounstein is currently a managing director of CTRLCFO, LLC, a firm Mr. Brounstein founded in 2016 to support funded start-ups in life science and technology. From 2008 to 2011, Mr. Brounstein was Chief Financial Officer of NewCardio, Inc., a microcap public company in the cardiology space, and, over his career, he has been with nine other companies in life science or technology, holding positions including Chief Financial Officer, Chief Operating Officer, Treasurer and Accounting Manager. From June 2001 through November 2007, Mr. Brounstein held several positions at Calypte Biomedical Corporation, a publicly traded medical device company, including Chief Financial Officer and Executive Vice President. In January 2007, Mr. Brounstein was appointed as the National Member Representative for the 2007 COSO Monitoring Project, which published new guidelines for monitoring internal financial controls in February 2009; Mr. Brounstein subsequently was a member of the FEI task force that issued the updated COSO Internal Control Framework in 2013. In March 2005, Mr. Brounstein was appointed to the SEC Advisory Committee on Smaller Public Companies. Mr. Brounstein earned his Certified Public Accountant (CPA) certification while working at Arthur Andersen LLP, formerly a public accounting firm. Mr. Brounstein holds a B.A. in accounting and an M.B.A. in finance, both from Michigan State University.

Ken Persen, HeartBeam’s Chief Technology Officer, combines over 28 years of experience in the medical device and digital health industries in engineering and senior management positions. Mr. Persen has been involved in several companies in Cardiac Rhythm Management, holding positions including Chief Executive Officer, Chief Technology Officer, Executive Vice President and Director of Engineering. Since 2016 and prior to joining HeartBeam, Mr. Persen was the Chief Technology Officer at LIVMOR, Inc., a digital health company. In addition, from 2016 through November 2021, he was also Chief Executive Officer of LIVMOR. Prior roles included Director of Engineering at Cameron Health (acquired by Boston Scientific), a late-stage medical device start up, and engineering and management positions at Guidant Corp. (acquired by Boston Scientific), a large medical device manufacturer. He has an undergraduate degree from University of Minnesota, Duluth, with a BA in Computer Science.

HeartBeam Inc. (NASDAQ: BEAT), closed Thursday's trading session at $2.3, up 6.4815%, on 108,470 volume. The average volume for the last 3 months is 235,756 and the stock's 52-week low/high is $1.06/$3.3893.

Recent News

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

Israel-based SuperCom is promoting public safety founded on the strength of its superior electronic monitoring ("EM") technology platform

SuperCom's PureSecurity platform uses GPS to track the movements of individuals monitored by law enforcement on pretrial and probationary release from jail custody, including a 3-D elevation blueprint that is useful to apartment dwellers and office workers

The importance of GPS-enabled tracking was highlighted in a recent New York State domestic violence case that reportedly led to a woman's death when her accused attacker was freed from GPS monitoring

The PureSecurity platform not only alerts supervising law enforcement about an EM-monitored individuals' movements, but also provides alerts via cell phone to potential victims to help them seek safety in a timely manner

SuperCom (NASDAQ: SPCB) is leveraging its electronic monitoring ("EM") platform as a cutting-edge solution that is ahead of the curve in what is still a niche market. Its client list in Europe and the United States is continuing to grow. EM technology is becoming increasingly popular among European governments to advance the social inclusion of criminal offenders through probationary services, reducing recidivism. The company recently announced $2.6 million in new orders from European governments.

"We are delighted to continue strengthening our collaboration with European governments," said SuperCom President and CEO Ordan Trabelsi. "It highlights our leadership in the electronic monitoring sector and our ability to consistently meet our clients' evolving needs. We remain committed to ensuring successful project execution and fostering lasting partnerships with governments worldwide… These repeat orders underscore our customers' confidence in SuperCom's cutting-edge technology and our unwavering commitment to improving public safety."

To view the full article, visit https://ibn.fm/AEuMr

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More

 

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Thursday's trading session at $3.4, up 0.591716%, on 34,633 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.3893/$.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into securities purchase agreements with institutional investors to raise approximately $3 million. The funding will come from the sale of 17,647,060 shares of common stock, priced at $0.17 per share, in a registered direct offering. The proceeds will be used for general corporate purposes and working capital. A.G.P./Alliance Global Partners is acting as the sole placement agent for the transaction, which is expected to close today, Oct. 24, 2024, pending customary conditions.

To view the full press release, visit https://ibn.fm/ORcEo

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $0.1456, up 3.2624%, on 71,973,679 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0955/$6875.00.

Recent News

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF)

The QualityStocks Daily Newsletter would like to spotlight Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF).

The Black Sea basin is estimated to contain significant amounts of natural gas.

Being geographically closer to European markets and offering untapped potential, the Black Sea is ideally positioned to become a crucial supplier of natural gas to the area.

With active projects in the region, particularly in the South Akçakoca Sub-Basin ("SASB") off the coast of Türkiye, Trillion Energy is capitalizing on the area's promise.

In recent years, the Black Sea has emerged as a critical region for natural-gas exploration and development. As Europe seeks to diversify its energy sources, reduce dependency on Russian natural gas and transition to cleaner energy solutions, the untapped resources in the Black Sea offer a significant opportunity. Trillion Energy International (CSE: TCF) (OTCQB: TRLEF), a company focused on oil and natural gas production for Europe and Türkiye, is planning strategic growth in the area, hoping to take full advantage of the potential the Black Sea offers for natural-gas production (https://ibn.fm/bsRe8).

Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF), along with its consolidated subsidiaries, is a Canadian oil and gas exploration and production company with operations primarily focused in the Republic of Türkiye.

Headquartered in Canada, the company owns 49% of the SASB natural gas field, which is producing critical domestic supply of natural gas during Europe’s ongoing energy shortages. It also holds a 19.6% (except three wells with 9.8%) ownership interest in the Cendere Oil Field and has a farm-in agreement to earn 50% interest in three oil exploration blocks in southeast Türkiye called Cudi-Gabar.

Trillion Energy utilizes state-of-the-art technology and ingenious practices to produce and distribute oil and natural gas while still maintaining a commitment to sustainable and responsible operations. Whether through the development of new projects or optimizing existing assets, the company continues to seek new and innovative ways to drive growth and value for its stakeholders.

Headquartered in Vancouver, British Columbia, Trillion Energy is led by seasoned professionals who collectively boast over a century of energy exploration and development experience.

Projects

SASB Gas Field

The SASB Gas Field is producing and delivering critical domestic supplies of natural gas as energy shortages grip Europe due to Russia’s invasion of Ukraine.

Located in the southwestern Black Sea, the SASB gas field consists of numerous conventional natural gas pools located in shallow water. The fields have produced over 43 billion cubic feet (BCF) since initial development in 2007 and continue to provide much needed energy to Türkiye and the EU. Total infrastructure to date, including production platforms, pipelines, initial wells and gas processing plant, cost in excess of $600 million.

Trillion Energy is redeveloping the field with a strategic planned program of approximately 17 wells which commenced in 2022. Phase B of the program, targeted for 2024/25, consists of the re-entry of five legacy wells to drill sidetrack development wells and one exploration stratigraphic well.

Cendere Oil Field

Trillion Energy’s Cendere oil field is a long-term, low decline, stable oil production field located in Türkiye. The company has a 19.6% interest in the field, except for three wells in which its interest is 9.8%.

Cash flow after operating costs from the field is $120,000 to $140,000 per month, with average current production netting the company 110-120 barrels of oil per day. Estimated remaining Cendere oil reserves total 1.5 million barrels (0.277 million barrels net Trillion Energy).

The gross value of Trillion Energy’s interest is estimated at $13.85 million (NPV10).

Cudi-Gabar

Trillion Energy’s 10-well oil exploration drilling program is occurring on three prospective oil blocks located in the prolific Cudi-Gabar oil province in southeast Türkiye. The total area of the three blocks is 374,325 acres.

Trillion Energy’s potential 50% working and revenue interest in the blocks is earned by paying 100% of the work program costs. The company will operate the exploration program.
During 2023/24, Trillion Energy will shoot 351 kilometers of 2D seismic (150 km already shot on the eastern block) and drill four wells. The remaining six wells will be paid 50% by Trillion and 50% by the company’s partner. The oil blocks are surrounded by more than 10 major oil discoveries, half of which are recent.

Market Opportunity

A January 2024 report by Emergen Research, a market research and consulting company, estimated the global natural gas market at $310.5 trillion in 2022 and projected the market will be worth $443.8 trillion by 2032, achieving a CAGR of 3.7% during the forecast period. Increasing global economic activity and rising electricity consumption are key factors driving revenue growth of the market, according to the report.

Trillion Energy reports strong demand for natural gas in Türkiye, which is the seventh-largest natural gas consuming country in the world. Türkiye currently imports 98% of the natural gas it consumes, with about 60% of those imports coming from Iran and Russia.

Management Team

Dr. Arthur Halleran is CEO and Director of Trillion Energy. He has a Ph.D. in Geology from the University of Calgary and 44 years of petroleum exploration and development experience. His international experience includes work in Canada, Colombia, Egypt, India, Guinea, Sierra Leone, Sudan, Suriname, Chile, Brazil, Bulgaria, Türkiye, Pakistan, Peru, Tunisia, Trinidad Tobago, Argentina, Ecuador and Guyana. Dr. Halleran has worked for Petro-Canada, Chevron, Rally Energy and United Hydrocarbon International Corp. In 2007, he founded Canacol Energy Ltd., now the largest natural gas producer in Colombia.

Al Thorsen is COO of Trillion Energy. He is responsible for production operations of the SASB gas field, as well as future drilling activities in Türkiye and abroad. Highlights of his career include Valeura Energy Inc. as operations manager in Türkiye; Journey Energy, leading a production team; Rio Alto Exploration as country manager and production manager; Zargon Oil and Gas as VP of Operations; Orleans Energy as VP of Operations; and Central Petroleum as COO. He holds a Bachelor of Science in Petroleum Engineering from Montana College of Mineral Science & Technology.

Trillion Energy International Inc. (OTCQB: TRLEF), closed Thursday's trading session at $0.06385, up 1.3492%, on 47,620 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.055/$0.512.

Recent News

Energy and Water Development Corp. (OTCQB: EAWD)

The QualityStocks Daily Newsletter would like to spotlightFathom Energy and Water Development Corp. (OTCQB: EAWD) .

A new report shows that about nine in ten firms that manufacture building products generate a significant portion of their revenue from sustainable services and products. This is a remarkable management indicator, especially as the world increases its focus on the importance of eco-friendly and energy-efficient solutions in construction. Decisions made now about how buildings are constructed and maintained will determine this field's energy consumption and emissions in the long-term. At the moment, buildings make up more than 30% of energy consumed globally, with the industry being pressured to meet net-zero targets as stipulated in the Paris Agreement. Overall, the industry's gradual shift toward sustainability continues to align with increasing market demand for eco-friendly solutions and global net-zero goals. As sustainability continues to drive growth in revenue, firms leading this transition may benefit from increased consumer awareness and regulatory incentives. This data coming out of Europe can serve as an encouragement to various enterprises like Energy and Water Development Corp. (OTCQB: EAWD) that have focused on providing products and services which may not necessarily be in the construction industry but nonetheless hinge on sustainability. The revenue is bound to keep increasing, and growth will be inevitable.

Energy and Water Development Corp. (OTCQB: EAWD) is a green-tech engineering solutions company focused on delivering water and energy to extreme environments. The company builds water and energy systems out of already existing, proven technologies, utilizing its patent-pending systems configuration and technical know-how to customize solutions to meet clients’ needs. To date, two water systems have been sold and deployed in Mexico and Germany, and the company is working to fulfill additional orders.

Using its patent-pending design, EAWD is working to build and operate off-grid EV charging stations in Germany. The company is a United Nations-accredited vendor and offers design, construction, maintenance and specialty consulting services to private companies, government entities and non-government organizations for the sustainable supply of energy and water.

EAWD focuses on three main aspects of the water and energy business: (1) generation, (2) supply and (3) maintenance. The green tech industry is constantly evolving due to ongoing and increasing water scarcity, as well as increased energy needs in the world. Therefore, the company believes that by designing sustainable and renewable solutions to these problems, EAWD will become an essential component of a rapidly growing industry with many new markets.

EAWD’s approach seeks to assist businesses with the growth and development of their general operations by ensuring the efficient, profitable and sustainable supply and generation of water and energy, allowing its potential customers to focus on their business while adopting strategies of sustainability.

By using the state-of-the-art technological solutions and technologies identified, designed and provided by EAWD and its collaborators, the company believes that its potential clients will be free to focus on the performance of their operations, as well as with the water and energy consumption or generation regulations within their industries.

EAWD is headquartered in Saint Petersburg, Florida, with operations in Germany and Mexico.

Products

In view of the increased worldwide demand for water and energy, EAWD’s business goals are focused on self-sufficient energy-supplied water generation and green energy production. To accomplish this, the company set out to establish an outsourcing green tech platform to commercialize its state-of-the-art technologies while providing engineering and technical consultation services to design the most sustainable technological solutions that can provide water and energy.

The company has sought potential collaboration with green tech research and development centers in Europe and has established its operating subsidiaries in Hamburg, Germany, where EAWD has started to assemble its patent-pending innovative off-grid, self-sufficient energy supply atmosphere water generation (AWG) systems.

EAWD Deutschland and EAWD Logistik operate in Hamburg, Germany, to meet the increasing demands of water and energy generation projects around the world, as well as to operate the solar-powered EAWD Off-Grid EV Charging Stations, EAWD’s newest product.

The company expects to offer sustainable added value to each project it takes on, while generating revenue from the sale of EAWD Off-Grid AWG Systems, EAWD Off-Grid EV Charging Stations, EAWD Off-Grid Power Systems and EAWD Off-Grid Water Purification Systems; royalties from the commercialization of energy and water in certain cases; and licensing of its innovated technologies, along with its engineering, technical consulting and project management services.

EAWD continues to be a development stage company. It presently assembles its EAWD Off-Grid AWG Systems and EAWD Off-Grid EV Charging Stations at its workshop in Germany and outsources most of its engineering and technical services, as well as services relating to the promotion, sale and distribution of its products.

Market Opportunity

According to a report by Allied Market Research, a global market research, consulting and advisory firm, the worldwide green technology and sustainability market was valued at $10.32 billion in 2020 and is projected to reach a value of $74.64 billion by 2030, growing at a CAGR of 21.9% during the forecast period.

A surge in environmental awareness and increasing concerns among organizations and individuals about climate change drive the growth of the market. Furthermore, an increase in consumer and industrial interest for the use of clean energy resources are among some of the major factors expected to boost growth of the market in the coming years, according to the report.

The expected rise in favorable government and private initiatives to tackle climate change and air pollution represent an opportunistic factor of the market. An increase in energy consumption and rise in greenhouse gas emissions are major factors that drive the development of green technology innovations, the report states.

Management Team

Irma Velazquez is CEO and Vice Chair at EAWD. She brings certified expertise in sustainable development and large-scale project management to the company. She formerly worked for United Nations agencies including the World Health Organization, Farmaciens Sans Frontieres, Red Cross and Crescent Societies, where she served in the positions of Information Technology Manager, Sustainable Development Manager, Programme Manager and Disaster and Crisis Management Coordinator. She has a master’s in sciences from the Erasmus University of Rotterdam. She speaks French, English and Spanish.

Ralph Hofmeier is Chief Technology Officer and Chairman at EAWD. He brings a mechanical engineering background to the company and previously served as President of Powermax Energy & Business Solutions Inc. When that company merged with EAWD, he served as President and CEO of Directors of EAWD. Over the last 20 years, he has established and developed several multinational companies in green tech distribution and commercialization. He speaks German and English.

Energy and Water Development Corp. (OTCQB: EAWD), closed Thursday's trading session at $0.0027, up 8%, on 2,551,462 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.002395/$0.12.

Recent News

GEMXX Corp. (OTC: GEMZ)

The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

Last week saw the price of gold hit a new high as uncertainty about the upcoming presidential elections in the U.S. and conflict in the Middle East prompted investors to seek out safe haven assets. Experts believe that an image of global instability often prompts investors to buy more gold in a bid to safeguard their finances. A senior market analyst at Kitco Metals, Jim Wyckoff, explains that the lack of consensus among the public or the market on which candidate will win the election is causing uncertainty, which often triggers demand for gold as a safe haven asset. The CME FedWatch Tool notes that the chances of an additional quarter-point decrease in rates in November stand at over 90%. Global X analyst Trevor Yates explains that lower rates of interest normally coincide with higher prices of gold. It would be interesting to know how companies like GEMXX Corp. (OTC: GEMZ) which not only mine gold but also manufacture finished goods like jewelry from the gold could be impacted by the prices of gold reaching new highs every so often.

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.

 

GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Thursday's trading session at $0.0144, even for the day, on 20 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0023/$0.0735.

Recent News

GolfLync Inc.

The QualityStocks Daily Newsletter would like to spotlight GolfLync Inc.

For golfers, traveling often comes with the challenge of finding great courses and players in unfamiliar locations. Whether you're heading out on vacation, a business trip, or simply visiting friends or family, GolfLync's innovative travel feature ensures you can always tee off for a great time, no matter where you are.

With this feature, GolfLync users can easily discover local golf courses and available tee times that match their preferences. Gone are the days of scrambling to find the right course or wondering who's available to play or what stranger you might be paired up with. GolfLync's travel feature, along with their new CourseLync pages for each course, allows you to seamlessly explore nearby courses in your destination city, check reviews, course conditions, and organize a round in just a few taps.

Beyond just planning tee times, GolfLync enhances the social aspect of golf while traveling. You can instantly connect with other GolfLync users who are also looking for a game, whether it's locals in the area or fellow travelers. This way, you can still enjoy a competitive or casual round, even when you're away from your usual group.

GolfLync's travel feature is perfect for golfers who want to make the most of their time away from home without missing out on their passion for the game. It's like having a personal golf concierge at your fingertips, allowing you to turn any trip into a golfing adventure. Simply set your location, browse courses, find players, and hit the green with ease, all through the GolfLync app.

So, next time you're packing your bags, don't forget your clubs—GolfLync will take care of the rest!

You can download the GolfLync app using the following text-anchored links:

Android: GolfLync – Apps on Google Play 

iPhone: GolfLync 

For more information about GolfLync, visit GolfLync, download the app, and connect with community on FacebookX and LinkedIn

GolfLync Inc. matches golfers looking for a game through the company’s smartphone app, GolfLync. The company bills GolfLync as “the social network for golfers,” matching golf games and players similar to the way a dating app matches those looking for romance.

The app allows like-minded golfers to connect for a game simply by logging in. GolfLync helps golfers who are looking to grow their golf network find other players with similar interests and on course preferences. Whether you have recently moved to a new area and are looking for new golfing buddies, travel frequently and would like to play a round of golf while on the road, or just want to meet new golfers in your area, GolfLync is your answer. Spouses who enjoy golfing together can find other golfing couples to tee it up with. For a regular group that finds itself unexpectedly down a player, GolfLync can help find that last-minute addition to complete the foursome.

The company is based in Scottsdale, Arizona.

GolfLync App

GolfLync was created for golfers of all skill levels and preferences to connect with compatible players of similar skill. Golfers can find a tee time through GolfLync, join existing tee times and create new leagues. The app allows golfers to meet fellow players before committing to spend four hours on the course with them. GolfLync allows users to find new golf friends based on their preferences, such as walking or riding a cart, listening to music, friendly wagering, imbibing a favorite beverage at the 19th Hole and more. GolfLync is available for both Android and iOS as a free download.

Download on Apple App Store   Get it on Google Play

Market Opportunity

According to a report by Statista, a leading provider of market and consumer data, in 2022, the number of people participating in golf in the United States reached 25.6 million, with 15.5 million additional players participating in off-course activities like driving ranges. In 2020, over 502 million rounds of golf were played in the U.S. alone. The game, traditionally dominated by male players, is changing, with increased interest from women golfers driven by social media influencers around the game.

Lumen Sports puts the total number of golf courses in the U.S. at more than 16,700. According to Lumen, about 75% of those are public courses open to all golfers, with the rest considered private golf clubs that require a membership.

 

Management Team

Noah DiPasquale is a co-founder and CEO of GolfLync Inc., leading the marketing and operations of the platform. He is also the founder and CEO of Epic Golf Club, a premier national membership and private golf society which partners with hundreds of top tier private golf clubs allowing Epic members access to their courses and recently founded the Epic Foundation, a Scottsdale-based 501c3. He holds a B.S. in Business Administration, Management and Operations from the W.A. Franke College of Business at Northern Arizona University and an MBA in Marketing from the University of Phoenix.

Michael Quiel is a co-founder of GolfLync Inc. and the President of the organization. He leads the application development and research teams. Michael understands how to build successful companies. His deep knowledge of investment banking, finance and building successful business partnerships is unparalleled. He’s an expert at capital formation and growth hacking companies. He has raised over $250 million in capital and taken multiple companies public.

Recent News

chart

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)

The QualityStocks Daily Newsletter would like to spotlight McEwen Mining Inc. (NYSE: MUX) (TSX: MUX).

McEwen Mining (NYSE: MUX) (TSX: MUX) subsidiary McEwen Copper has secured an additional $35 million investment from Nuton LLC, a Rio Tinto Venture, as part of its ongoing private placement financing. This second tranche brings the total raised to $56 million, with Nuton now owning 17.2% of McEwen Copper. The funds will support the development of the Los Azules copper project, with a feasibility study expected by mid-2025. McEwen Copper's post-money market value is now $984 million, with major shareholders including McEwen Mining, Stellantis, Nuton, and Rob McEwen.

To view the full press release, visit https://ibn.fm/jnOlJ

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is an asset rich diversified gold and silver producer in the Americas with a large exposure to copper through its subsidiary, McEwen Copper, owner of the Los Azules copper deposit in Argentina, believed to be the 8th largest undeveloped copper resource in the world.

Led by a management team with a track record of success, MUX owns and operates mines in some of the most prolific gold producing regions of the Americas. The company proactively took cost-saving measures months ago to lower expenses and increase production across its portfolio of gold assets, driving some production costs below industry averages. Gold and copper prices, already in an upswing, are forecast to enter an explosive uptrend over the next couple years. Drawing from its experience, McEwen Mining planned, prepared and laid the groundwork to capitalize on this emerging opportunity.

The company currently holds a Zacks Rank #1 (Strong Buy), placing it in the top 5% of over 4,000 stocks ranked by Zacks, based on trends in earnings estimate revisions and EPS surprises. Seldom is management so aligned with investors’ interests and committed to the company’s success. With a combined investment of over $220 million, CEO Rob McEwen holds a 17% ownership stake in McEwen Mining and a 13% ownership in McEwen Copper. Acclaimed in the mining industry, McEwen founded Goldcorp, where he increased the company’s market capitalization 160 times – from $50 million to over $8 billion. That same vision and tenacity led MUX in creating McEwen Copper.

For McEwen Mining shareholders, beyond the company’s exposure to gold upsurges, its 47.7% stake in McEwen Copper is expected to be a blockbuster, turbocharging MUX by creating the world’s next prolific copper unicorn.

McEwen Copper

With continuous industrial need, new critical demand for copper is rapidly emerging, increasingly driven by the green energy transition. The price of copper rose from a low of about $2 per pound in 2020 to over $4.60 per pound in May 2024, and strong demand is expected to intensify. A study by S&P Global, titled The Future of Copper: Will the Looming Supply Gap Short-circuit the Energy Transition?, projects global copper demand to nearly double over the next decade, from 25 million metric tons today to about 50 million metric tons by 2035. Based on current trends, S&P Global forecasts annual supply shortfalls to reach nearly 10 million metric tons in 2035.

McEwen Mining owns a 47.7% equity stake in McEwen Copper, the holder of a 100% interest in the Los Azules copper project in San Juan, Argentina, which is ranked the 8th largest undeveloped copper deposit in the world. Current copper resources at Los Azules are estimated at 10.9 billion pounds at a grade of 0.40% Cu (Indicated category) and an additional 26.7 billion pounds at a grade of 0.31% Cu (Inferred category). McEwen Copper also owns a copper exploration project in Nevada, USA, called Elder Creek.

In a 2023 Preliminary Economic Assessment (PEA), Los Azules was estimated to have a 27-year life, producing an average of 322 million lbs. of copper cathode annually, at a cash cost of $1.07 per lb. of copper, in the lowest quartile of the copper cost curve. The project could ultimately become an even larger mine with a longer life, since the extent of mineralization has not been fully assessed on the property.

The project’s 2023 PEA presents a distinctly different development strategy from a prior PEA published in 2017. By proposing a heap leach project using solvent extraction-electrowinning instead of the previously detailed mine with a conventional mill and flotation concentrator, McEwen Copper aims to decrease its environmental footprint and reduce permitting risk, albeit with a lower overall copper recovery, slightly higher unit costs and a delay in immediate cashflow due to extended leach cycles.

After securing a $25 million investment from mining giant Rio Tinto’s technology arm, Nuton LLC, McEwen Copper closed its non-brokered, private placement offering of $82 million in August 2022. Shortly after, in February 2023, Nuton agreed to invest an additional $30 million into McEwen Copper, and in October 2023, Nuton once again expanded its stake, investing an additional $10 million to bring its ownership position in McEwen Copper to 14.5%.

“We are extremely pleased to have Nuton’s strong continued participation in McEwen Copper,” Rob McEwen stated in a news release. “Together we are exploring new technologies that save energy, water, time and capital in the pursuit of delivering green copper to Argentina and the world, a product that will contribute to the electrification of transportation and the protection of our atmosphere.”

Also in February 2023, FCA Argentina S.A., a subsidiary of Stellantis N.V., one of the world’s leading automakers, invested ARS $30 billion in McEwen Copper. In October 2023, Stellantis invested an additional ARS $42 billion, bringing its current stake in McEwen Copper to 19.4%.

“We are delighted to have Stellantis as a partner in the future development of our Los Azules copper project,” Rob McEwen said of the investment. “Together, we share a vision to build a mine for the future based on regenerative principles that can achieve net-zero carbon emissions by 2038.”

Following the capital raise, McEwen Copper is well-funded to advance its Los Azules Project, with a Feasibility Study planned for Q1 2025. MUX strategically reduced its interest to increase its treasury, in order to reduce debt and fund the further development of its gold and silver assets.

Gold & Silver Projects

The Fox Complex

McEwen Mining owns a 100% stake in the Fox Complex in the heart of a prolific gold district in Timmins, Canada.

“When MUX bought the Fox Complex, in late 2017, it was a distressed asset with a history of high operating cost/oz. While it has taken longer than I expected, the cost to produce an ounce of gold is significantly lower,” CEO Rob McEwen stated in a news release.

McEwen Mining issued 2024 guidance for its cash cost/oz at the Fox Complex of $1,225-1,325 on annual production of 40,000-42,000 GEOs. Fox Complex produced 44,450 GEOs in 2023, which was within the company’s guidance range.

Located in one of the most prolific gold production areas in the world, along the Destor-Porcupine Fault Zone within the Abitibi Greenstone Belt, the Fox Complex includes the Black Fox mine and Froome mine which together have yielded over 1,000,000 ounces of gold to date. Also, the complex includes the Grey Fox and Stock deposits that have over 1,800,000 ounces in gold resources. The 2.7-billion-year-old Abitibi Greenstone Belt, formed by ancient volcanic activity, has proved to be one of the world’s richest and most abundant gold regions, with a total gold content currently estimated at over 300 million ounces.

In 2024, MUX commenced development of underground ramp access to the Stock orebodies at the Fox Complex. This development will become the primary source of feed following the completion of mining the Froome deposit in 2026. As part of the future mining sequence initiative, the company has already reported a 31% year-over-year increase of gold resources at Stock West and Stock Main (historical Stock Mine), with confirmation of good grading structures plunging to depth. It has also identified Stock East as a potential new near-term source of future revenue.

The Gold Bar Mine

McEwen Mining owns a 100% stake in the Gold Bar mine, located in an area well known for gold production, the southern Roberts Mountains of the Battle Mountain-Eureka-Cortez gold trend in Eureka County, Central Nevada. The Gold Bar mine is on the same geological structure, 25 miles south of Nevada Gold Mines, a Barrick-Newmont joint venture, part of the Cortez-Goldrush complex. This complex contains estimated reserves and resources of over 50 million gold ounces, with an annual production of 1,000,000 gold ounces.

Gold Bar had been mined between 1991 and 1994, producing 134,000 gold ounces. A new facility was built by MUX in 2019. Gold Bar accounted for 42,700 GEOs in 2023, within the company’s guidance for the year. For 2024, McEwen Mining issued guidance of 40,000-43,000 at a cash cost of $1,450-1,550. The first half of the year is expected to deliver higher production relative to the second half, due to a scheduled waste stripping phase in the Pick pit, in preparation for the 2025 mining program.

Notably, in April 2024, McEwen Mining announced its entry into a definitive agreement and plan of merger with Timberline Resources Corporation (TSX.V: TBR) (OTCQB: TLRS) in a transaction valued at roughly $18.8 million. The merger with Timberline is expected to augment McEwen’s existing portfolio of development and exploration projects in Nevada, leveraging synergies between Timberline’s projects and the Company’s Gold Bar mine.

El Gallo/Fenix

Project Fenix is the proposed redevelopment plan for McEwen Mining’s El Gallo Complex in Mexico. There is a long history of mining in this region. MUX began operating it as an open pit, heap leach mine in 2013, which produced 281,000 gold equivalent ounces at average cash cost of $655 per ounce. Due to the transition to deeper sulfide mineralization that is not amenable to heap leaching, mining activities ceased in the second quarter of 2018 and residual heap leaching followed until mid-2022. The redevelopment plan envisions constructing a mill at the existing mine site that will initially reprocess the existing heap leach material, then transition to open pit mining and processing of the sulphide mineralization. The company recently acquired a complete process plant on very advantageous terms that has considerably reduced the projected capital requirements for the project.

CEO Rob McEwen stated in a news release, “This acquisition has made Fenix more attractive to build and could provide a new long life mine for McEwen Mining.”

The initial development approach is to build a mill to reprocess the material on the heap leach pad and produce approximately 17,000 oz of gold annually for eight years. Construction of the Fenix project is expected to begin in the second half of 2024.

San José Mine

McEwen Mining is a 49% owner and non-operator of the San José gold and silver mine, located in Santa Cruz province, Argentina, encircling Newmont’s prolific Cerro Negro (approx. 300,000 gold ounces produced in 2023). This high-grade underground mine has been operating since 2007 and currently has an expected life of six years with a reserve grade of 296 gpt silver and 5.4 gpt gold.

Exploration is continuing to extend high-grade veins and discover new veins at the complex. San José’s drilling programs to define additional resources and reserves have a long history of success due to a high vein density, aided by good geophysical response from hidden veins.

Production guidance for 2024 for MUX’s 49% interest is 50,000-60,000 GEOs. As a minority shareholder in the mine, MUX equity accounts for its investment in San José, and receives 49% of the dividends from the mine’s free cash flow.

Market Outlook

Mining stocks suffered significant losses in the wake of the COVID-19 pandemic. However, this has turned, and many analysts now forecast a gold bull market in 2024 and beyond.

“The operating challenges we faced in recent years have severely damaged our credibility with our shareholders and the market. As a result, few investors have taken a close look recently at our assets,” Rob McEwen said in a news release. “If they did, I believe some would see the potential value that I see today… I believe there is considerable potential value in MUX, and that is a big reason why I have a personal financial commitment of $220 million in MUX and McEwen Copper.”

Management Team

Robert R. McEwen is Chairman, CEO and Chief Owner of McEwen Mining. He has been associated with the gold industry all his career, with his first 18 years in the investment industry and, since 1990, as CEO of several gold mining companies. He founded Goldcorp and took that company from a $50 million market capitalization to more than $8 billion. He owns 17% of McEwen Mining and is in complete alignment with investors – his investment in MUX and McEwen Copper is $220 million and he takes an annual salary of only $1. He was awarded the Order of Canada and the Queen Elizabeth’s Diamond Jubilee Award, was inducted into the Mining Hall of Fame, was named an Ernst and Young Entrepreneur of the Year and has Honorary Doctor of Law degrees from York University and Western University.

William Shaver is interim COO and a Director of McEwen Mining. He has decades of management and executive experience in mine design, construction and operations. He was a founder of Dynatec Corporation, which became one of the leading contracting and mine operating groups in North America. In 2013, he was recognized as Ernst and Young Entrepreneur of the Year. Most recently, he served as COO of INV Metals. He is a Professional Engineer with a B.Sc. in Mining Engineering from Queens University.

Perry Ing is interim CFO at McEwen Mining. He has 25 years of experience in the Canadian mining industry. Over the past 15 years, he has held positions as CFO of Mountain Province Diamonds, Kirkland Lake Gold and McEwen Mining. Prior to that, he worked at Barrick Gold and Goldcorp and started his career in the mining practice at PwC. He has a Bachelor of Commerce from the University of Toronto and is a Chartered Professional Accountant in Canada and Certified Professional Accountant in the U.S.

Adrian Blanco S. is the company’s Director of Operations for America and Mexico. He has extensive international experience in several industrial sectors and has held executive positions in Mexico, the United States, Peru and Argentina. He joined the McEwen Mining team in 2015 and has led a successful business transformation toward operational discipline, best business practices and financial profitability at subsidiaries Compañia Minera Pangea and McEwen Mining Nevada. He graduated from an Executive Management Program at IPADE and Harvard Business School.

Michael Meding is Vice President and General Manager of McEwen Copper. He has over 20 years of international experience, primarily with major mining companies such as Barrick Gold and Trafigura, including extensive experience with project development and operations in Argentina. While at Barrick Gold’s Veladero mine in Argentina, Mr. Meding played a key role in the turnaround, extension of the mine life and subsequent strategic partnering with Shandong Gold. He holds an MBA from Indiana University in Pennsylvania and an MBA from the Leipzig Graduate School of Management in Germany.

McEwen Mining Inc. (NYSE: MUX), closed Thursday's trading session at $10.7, off by 1.1091%, on 603,080 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $5.92/$12.50.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis ("ALS") and multiple sclerosis ("MS"), recently announced an upcoming meeting with U.S. Food and Drug Administration ("FDA") leadership. The focus is to discuss Clene's CNM-Au8® biomarker and related clinical and survival data for ALS. "FDA's Director of the Office on New Drugs, the Director of the Office of Neuroscience, and the Division of Neurology 1 (‘DN1') review team, as well as recognized key opinion leaders in ALS, biostatistics and biomarkers," will attend the meeting according to a recent article.

"Clene looks forward to the opportunity to have experts present their views to the FDA and address questions on ALS biomarkers, related clinical endpoints and survival data, all of which Clene believes are essential for the understanding of its CNM-Au8," the company stated in a news release. Clene also voiced appreciation for the FDA's use of process and regulatory flexibility to obtain the best outcome for people living with ALS.

To view the full article, visit https://ibn.fm/3O2Zt

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Thursday's trading session at $5.27, off by 2.4074%, on 72,444 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.8181/$12.00.

Recent News

Brera Holdings PLC (NASDAQ: BREA)

The QualityStocks Daily Newsletter would like to spotlight Brera Holdings PLC(NASDAQ: BREA).

Brera Holdings recently announced that it has signed an exclusive letter of intent to acquire an Italian second division soccer club in the Serie B pro league

The company previously commissioned a valuation analysis that discusses Brera management's intention to acquire professional soccer teams

A conservative scenario contained in the analysis projects one-year 10x potential revenue growth, with accompanying implied share value increases, for Brea should it complete the potential acquisition

A best-case scenario, in which Brera acquires a second soccer club, projects a jump in revenue of over 20x one-year post acquisition

The report concludes by emphasizing that Brera's future appears promising

Brera Holdings (NASDAQ: BREA) announced in September 2024 that it had signed an exclusive letter of intent to acquire another professional soccer team, this one in Serie B, the Italian second division. The company is now completing due diligence for the potential acquisition. A previously conducted investment valuation analysis (https://ibn.fm/QFukR) details the potential impact of this acquisition, and possibly others, on Brera's revenue and valuation metrics.

Brera Holdings PLC (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.

Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the Internet Marketing Association awarded Brera FC with the Social Impact Through Soccer accolade at its IMPACT 5050 Conference, recognizing the club’s global perspective and positive contributions to society.

The company’s growth strategy focuses on unlocking value from undervalued sports clubs and talent, driving innovation, and generating socially impactful outcomes. Brera Holdings is actively expanding its Global Sports Group, acquiring professional football and other sports clubs in emerging markets such as Africa, Asia, and Europe.

By targeting top-division teams in less mainstream markets, Brera Holdings aims to strengthen its competitive position in regional tournaments, including those organized by the Union of European Football Associations (UEFA). These acquisitions are expected to enhance sponsorship revenues and create new growth opportunities.

Leveraging its expertise in capital raising and revenue generation, Brera Holdings also anticipates growing demand for its consulting services, providing advisory support to sports clubs, associations, investors, and others. Brera Holdings is headquartered in Dublin, Ireland, with additional offices in Milan, Italy.

Sporting Assets

Brera Holdings continues to grow its global sports portfolio with a series of strategic acquisitions and innovations, including the FENIX Trophy Tournament, a pan-European, non-professional football competition. Launched in September 2021 and organized by Brera FC, the tournament has been recognized by UEFA and described by BBC Sport as “the Champions League for amateurs.” In 2023, Brera FC hosted the tournament’s finals at Milan’s iconic San Siro Stadium.

In March 2023, Brera Holdings expanded into Africa by establishing Brera Tchumene FC in Mozambique. Starting in the country’s Second Division League, the team quickly earned promotion to Moçambola, Mozambique’s First Division League, by November 2023.

In April 2023, Brera Holdings further strengthened its European presence by acquiring a 90% stake in Fudbalski Klub Akademija Pandev, a first-division football team in North Macedonia. This acquisition provides access to two major UEFA competitions, solidifying the company’s position in European football.

Brera Holdings’ reach extends beyond football. In July 2023, it acquired majority ownership of UYBA Volley, an Italian Serie A1 women’s professional volleyball team, demonstrating its commitment to diversifying within top-tier sports.

In September 2023, Brera Holdings entered the Mongolian football market by acquiring Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team. For the 2024 season, the club was rebranded as Brera Ilch FC, further expanding Brera’s global footprint.

In January 2024, Brera Holdings initiated a proactive search for an Italian Serie B football club, aligning with its goal of bringing multi-club ownership opportunities to mass investors through its Nasdaq-listed shares.

In February 2024, the Brera Holdings Advisory Board was established with MLS founder and World Cup director Alan Rothenberg, luxury lifestyle executive Massimo Ferragamo, sports business leaders Paul Tosetti and Marshall Geller, and Italian football icon Giuseppe Rossi.

In June 2024, the North Macedonian women’s football club Tiverija Strumica officially became part of the Brera family with the establishment of a joint-stock company controlled by Brera Holdings called Women’s Football Club Tiverija Brera AD Strumica (“Brera Tiverija”). Brera Tiverija is now a wholly-owned subsidiary of Brera Strumica FC.

In September 2024 Brera announced that it signed an exclusive letter of intent to acquire an Italian Serie B club (the “LOI” and the “Club”). According to a CFA report published in June 2024, this expected strategic transaction, for an estimated purchase price of $21.6 million, would add first-year annual revenue of $10.8 million to Brera, and that revenue would likely increase by 25% each year for the next three years. The company’s capital valuation, projected the report, would also experience significant appreciation during this period.

In October 2024, Brera was recognized with the 2024 Social Impact Through Soccer Award at IMPACT 5050, an annual event honoring leaders and innovators who significantly impact their industries and communities. This is the second time Brera has won the award.

Market Opportunity

A report from IMARC Group, a global management consulting firm, reveals that the international football market generated approximately $3.3 billion in revenue in 2023, with projections to grow to $4.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.6%. Key drivers behind this growth include advancements in digitization, increasing sponsorship and partnership deals between brands and clubs, the rising interest in women’s professional soccer leagues, and the expansion of the e-sports and gaming sector.

In particular, Serie B Italian football clubs seem to present exceptionally attractive investment opportunities. As of September 2024, more than half of these clubs had appreciated between 80-100% in total market value, post-purchase.

As the world’s most-watched and most-played sport, soccer drives significant demand for football-related products and services, contributing to market growth. Broadcasting rights, sponsorships, and endorsement deals are also major revenue sources for clubs and organizations, with an expanding global fanbase generating new opportunities for financial growth, according to the report.

Management Team

With extensive experience in leadership and finance, Daniel McClory currently serves as the Executive Chairman and Director of Brera Holdings, PLC. He co-founded and held the position of Chief Executive Officer at Boustead & Company Limited, and previously served as the Managing Director, Head of Equity Capital Markets, and Head of China at Boustead Securities, LLC. Mr. McClory’s governance experience includes being a Board Director for USA Track & Field and a member of the Eastern Michigan University Champions Advisory Board. Mr. McClory’s expertise encompasses founding and financing equity capital markets, as well as navigating merger and acquisition transactions and initial public offerings. He holds a BS and MS from Eastern Michigan University, where he also received an honorary Doctor of Public Service. In addition to his professional qualifications, he is fluent in both English and Italian.

Pierre Galoppi serves as the CEO, Interim CFO, and director of Brera Holdings. With over 30 years of experience in strategic business and financial services, his career spans a variety of industries, including natural resources, aviation, cybersecurity, telecommunications, tourism, and international marketing. He has worked extensively across Latin America, the Caribbean, Canada, Europe, and the United States. Mr. Galoppi holds dual citizenship in Canada and Italy and is fluent in English, Spanish, Portuguese, Italian, and French. He earned a Bachelor of Commerce degree and an MBA from Concordia University in Montreal.

Maria Xing serves as the Head of Investments and Corporate Development. She is an executive who has specialized in MCO football (soccer) group investments for 777 Partners, where she was involved in sourcing, direct negotiations, due diligence, and closing deals, including acquiring a controlling stake in Brazilian Serie A football club, Vasco da Gama, and investing in Australian Premier League (“A-League”) side, Melbourne Victory FC. She also played a role in other professional sports franchise portfolio management, including topflight professional football clubs in Italy, France, Germany, and Belgium. Her background is in private equity, investment banking, and finance, with prior experience at The Raine Group, Credit Suisse, and EY (Ernst & Young), as well as previous sports industry experience at Liverpool Football Club in international business development. Ms. Xing earned an MBA from the Wharton School of the University of Pennsylvania and a B.S. from the New York University, Stern School of Business.

Additional Resources

Brera Holdings PLC (NASDAQ: BREA), closed Thursday's trading session at $0.94, off by 9.6154%, on 198,219 volume. The average volume for the last 3 months is 1.142M and the stock's 52-week low/high is $0.5111/$3.00.

Recent News

HealthLynked Corp. (OTCQB: HLYK)

The QualityStocks Daily Newsletter would like to spotlightFathom HealthLynked Corp. (OTCQB: HLYK) .

Andrew Witty, the CEO of UnitedHealth Group, gave his testimony on the ransomware attack on Change Healthcare to the Senate Finance Committee in June. The attack occurred in February of this year, with the initial point of entry for the ransomware being a server whose multifactor authentication hadn't been enabled. This is despite the fact that multifactor authentication is a standard practice for servers exposed to the public internet. After gaining access to the server, the ransomware then acquired access to the Microsoft Active Directory Server. This ransomware attack was a wake-up call to others in the healthcare industry, prompting them to review their cybersecurity and IT contingency plans and priorities in preparation for a similar incident. He added that they remained focused on working with consumers to increase transaction volumes and acquire new business using their secure, modern, and capable offerings. The ransomware attack suffered by Change Healthcare offers significant learning moments for other enterprises like HealthLynked Corp. (OTCQB: HLYK) on how critical it is to treat matters of data security as top priority.

HealthLynked Corp. (OTCQB: HLYK) is at the forefront of a transformative movement in healthcare, utilizing its extensive collection of health data to improve care for all. With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights. Through deep analysis of this data, HealthLynked’s AI capabilities help identify the root causes of diseases, tailor healthcare solutions to individual needs, and accelerate medical discoveries.

HealthLynked Corp. App

In addition to these capabilities, HealthLynked provides a user-friendly platform for booking healthcare appointments, similar to how OpenTable operates for restaurant reservations. This feature allows patients to conveniently book appointments with healthcare providers across the country, including options for telemedicine consultations, enhancing accessibility and efficiency in healthcare service delivery.

Strategically headquartered in Naples, Florida, HealthLynked operates through three primary divisions: Health Services, Digital Healthcare, and Medical Distribution. Each division supports the company’s mission to revolutionize patient care and health management. Positioned as a potential leader in healthcare AI, HealthLynked is dedicated to shaping the future of the industry over the next 20 years, driving significant advancements in healthcare accessibility and effectiveness through innovation and technology.

HealthLynked Corp. Reach

Strategic Initiatives and Operational Highlights

The company’s commitment to enhancing global health is evident in its dual goals: transforming healthcare through advanced technology and creating a patient-centric network that accelerates medical discoveries and the development of disease cures.

HealthLynked’s intellectual property portfolio is robust and strategically developed to enhance healthcare delivery and management. In March 2023, HealthLynked was granted a patent for a groundbreaking healthcare-specific wireless access point, known as the “Patient Access Hub.” This technology significantly improves the efficiency of healthcare practices by enabling real-time monitoring of patient flow within facilities. It intelligently determines patients waiting in exam rooms and calculates wait times, alongside other critical practice metrics. This system not only enhances patient experience by reducing unnecessary wait times but also optimizes resource allocation within healthcare settings.

Additionally, in October 2023, HealthLynked filed a patent application for its advanced AI program, ARI (Augmented Real-time Interface). ARI acts as a virtual doctor for patients, capable of performing medical intake, booking appointments, and providing personalized medical recommendations based on a patient’s medical history. By integrating these tasks, ARI streamlines the healthcare process, reducing the administrative burden on healthcare providers and ensuring that patients receive timely and tailored healthcare advice. This AI-driven interface enhances the accessibility and personalization of healthcare, embodying HealthLynked’s commitment to leveraging technology for better health outcomes. The company recently launched HealthLynked 3.2.0, an advanced version of its application, incorporating telemedicine, AI-driven personal healthcare guidance, and remote patient monitoring – setting a new standard in healthcare technology.

Market Position and Future Outlook

According to Facts and Figures Research, a research and consulting firm, the global market for patient-centric healthcare applications is projected to reach $41.6 billion by 2030, growing at a CAGR of 18.77% from 2022. HealthLynked’s offerings align perfectly with this expansive market opportunity, especially with increasing demands for digital health solutions and data management in healthcare.

HealthLynked’s strategic direction, spearheaded by its seasoned management team, is designed to leverage these market dynamics, enhancing patient engagement and healthcare efficiency on a global scale.

Management Team

Michael T. Dent, M.D., Founder, CEO, and Chairman, brings extensive experience from his foundational role at NeoGenomics and leadership in various healthcare and technology sector companies.

David Rosal, CFO, with previous senior roles at Teradata and McDonald’s Corporation, brings a wealth of expertise in financial and business integration strategies essential for growth and operational efficiency.

Chris Hall, CTO, with a strong background in global technology development from his time at Siemens and several patents to his name, is instrumental in driving the innovation and technological advancement at HealthLynked.

Bill Crupi, Operations Manager, has a proven track record in streamlining operations and enhancing productivity across multiple sectors within the healthcare industry. His expertise is crucial in maintaining the operational excellence that HealthLynked is known for.

Michael Paisan, Director of Investor Relations, leverages his extensive experience in finance and communications to enhance HealthLynked’s relationships with investors and stakeholders, ensuring transparent and effective communication of the company’s value and growth strategy.

Gagan Babber, Manager of Software Development, oversees the HealthLynked development teams based in the U.S. and India. With a robust background in engineering and software development, he plays a critical role in guiding the technological direction of HealthLynked’s products. His expertise in developing scalable, innovative software solutions is essential for driving the company’s technical initiatives forward and ensuring that HealthLynked stays at the forefront of digital healthcare technology.

HealthLynked Corp. (OTCQB: HLYK), closed Thursday's trading session at $0.035, off by 12.2807%, on 325 volume. The average volume for the last 3 months is 103,268 and the stock's 52-week low/high is $0.0031/$0.0999.

Recent News

Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF)

The QualityStocks Daily Newsletter would like to spotlight Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF).

Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF) is an advanced stage gold exploration company focused on proving and developing the substantial resource potential of its flagship Duquesne West Gold Project located in the Tier 1 district of the Southern Abitibi Greenstone belt of Rouyn-Noranda, Quebec. The Project has a 2011 historical mineral resource estimate of 727,000 ounces of Au at 5.42 g/t and an average thickness of 5.71 m*.

In 2023, with the use of AI (Artificial Intelligence), Emperor Metals created the first ever 3D mineralized and geological model, which illuminated the potential to add significant ounces to this deposit. Using these models, Emperor’s had a very successful 2023 drilling campaign of 8,579 m. In addition to laterally extending high grade zones by intercepting grades of 15.8 g/t Au over 10.8 meters, Emperor encountered intercepts of lower grade bulk tonnage in the host rocks (1.69 g/t Au over 25 m). This led to envisioning a different strategy of exploration and the revelation that a conceptual open-pit potentially overlies this high-grade gold deposit. Historic core sampling began (2,500 m) for discovering overlooked lower grade gold in the host rock around the high-grade lenses. Lower grade bulk tonnage gold improves the open-pit economics by reducing stripping ratios and adding overlooked incremental ounces for open pit mining.

Emperor Metals is set to begin a fully funded Phase II 8,000 m drilling program in May 2024. The company also plans on assaying an additional 8,000 m of historic core within the open pit model. Emperor is working toward producing an updated NI 43-101 Mineral Resource Estimate by Q1 2025.

The company is led by a dynamic group of resource sector professionals who have a strong record of success in evaluating and advancing mining projects from exploration through to production, attracting capital and overcoming adversity to deliver exceptional shareholder value.

Project

Emperor Metals has an option to earn 100% ownership of the Duquesne West Gold Project, a mineral claim package comprising 38 claims covering approximately 1,389 ha (3,432 acres) in Quebec.

The Duquesne West Gold Property is located 32 kilometers northwest of the city of Rouyn-Noranda and 10 kilometers east of the town of Duparquet. The property lies within the historic Duparquet gold mining camp in the southern portion of the Abitibi Greenstone Belt in the Superior Province.

Emperor is targeting the potential multimillion-ounce resource in a combination of conceptual open pit and underground mining scenarios. A Phase I drill campaign and historical core sampling program was completed in 2023, which included resource confirmation and exploration drilling, focusing on delineating and growing the resource toward development.

The property hosts a historical inferred mineral resource estimate of 727,000 ounces of gold at a grade of 5.42 grams per ton (g/t) and average stope thickness of 5.71 m. The mineral resource estimate predates modern Canadian Institute of Mining guidelines, and a Qualified Person on behalf of Emperor Metals has not reviewed or verified the mineral resource estimate. Therefore, it is considered historical in nature and is reported solely to provide an indication of the magnitude of mineralization that could be present on the property. The gold system remains open for resource identification and expansion.

Reinterpretation of the existing geological model was created using artificial intelligence and machine learning. This AI model shows the opportunity for additional discovery of ounces by revealing gold trends unknown to previous workers and the potential to expand the resource along significant gold-endowed structural zones. Multiple scenarios exist to expand additional resources, which include:

  • Underground High-Grade Gold
  • Open Pit Bulk Tonnage Gold
  • Underground Bulk Tonnage Gold

The Duquesne West-Ottoman property straddles the Porcupine-Destor gold localizing fault several kilometers east of the town of Duparquet. A number of previous drill campaigns have outlined an inferred resource of 4.17 million tons grading 5.42 g/t of gold (cut) or 6.36 g/t (uncut), as reported in the NI 43-101 report titled “Technical Report and Mineral Resource Estimate Update for the Duquesne-Ottoman Property, Quebec, Canada.”

Emperor Metals is funded for an 8,000-meter drilling program focusing primarily on adding ounces to the current resource within and lateral to the open pit model. An additional 8,000 m of historical core sampling and assaying is included in the budget to help build incremental ounces in the open-pit environment.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, to be worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

In May 2024, the market price of gold was approximately $2,340 per ounce.

Management Team

John Florek, P.Geol., is President, CEO and Director of Emperor Metals. He has more than 35 years of technical and senior management experience with major and junior mining companies, including roles as founder, vice president and director. He has helped identify and develop significant asset value for mines and exploration projects from grass roots through development. He has worked for several major mineral producers, including BHP, Placer Dome, Barrick, Teck and Detour Gold/Kirkland Lake Gold/Agnico Eagle.

Sean Mager is CFO and Director of Emperor Metals. He has worked more than 30 years in the mining sector, including extensive experience in corporate development, stakeholder relations, regulatory, financial and operations.

Alex Horsley is Head of Corporate Development and Director of Emperor Metals. He has more than 20 years of experience in the mining sector and capital markets with a focus on finance, marketing, management, corporate development and communications. He is founder and former CEO of Emperor Metals. He has assisted in raising more than C$40 million for exploration and development mining companies.

*Power-Fardy and Breede, 2011. The Mineral Resource Estimate (MRE) constructed in 2011 is considered historical in nature as it was constructed prior to the most recent Canadian Institute of Mining and Metallurgy (CIM) standards (2014) and guidelines (2019) for mineral resources. In addition, the economic factors used to demonstrate reasonable prospects of eventual economic extraction for the MRE have changed since 2011. A qualified person has not done sufficient work to consider the MRE as current. Emperor is not treating the historical MRE as current. The reader is cautioned not to treat it, or any part of it, as a current MRE.

Emperor Metals Inc. (OTCQB: EMAUF), closed Thursday's trading session at $0.062, up 12.7273%, on 50,350 volume. The average volume for the last 3 months is 65,876 and the stock's 52-week low/high is $0.055/$0.14505.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.